“A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) With Originator Adalimumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s29, https://doi.org/10.25251/skin.1.supp.28.